MissionIR Articles
-
VistaGen Therapeutics (VSTA) Announces 3 Significant Publications Supporting the Use of Embryonic Stem Cells for Drug Discovery and Development
VistaGen Therapeutics Inc., a biopharmaceutical company pioneering the use of embryonic stem cells as proprietary biological systems for discovery and development of novel drugs for the treatment of diabetes and neurological diseases, announced today three…
-
VistaGen Therapeutics (VSTA) Announces Positive AV-101 Preclinical Data Suggesting Potential for Parkinson’s Disease
VistaGen Therapeutics, Inc., a biopharmaceutical company developing drugs for treating neurological disorders and diabetes, announced today positive preclinical data supporting expanded applications of AV-101, the Company’s first in-class prodrug that regulates critical NMDA receptors in…
Search Articles
Latest Articles
- MissionIRNewsBreaks – Massimo Group (NASDAQ: MAMO) Reports Q3 2025 Net Income of $1.5 Million and 42% Gross Margin, Highlighting Strong Operational Turnaround
- MissionIRNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Launches HOPE Therapeutics’ One-Day TMS Protocol for Treatment-Resistant Depression in Florida
- MissionIRNewsBreaks – Datavault AI Inc. (NASDAQ: DVLT) Files Defamation Lawsuit Against Wolfpack Research and Founder Dan David
- MissionIRNewsBreaks – Lantern Pharma (NASDAQ: LTRN) CEO Discusses AI-Driven Cancer Drug Development in FintechTV Interview at NYSE
- Datavault AI Inc. (NASDAQ: DVLT) Drives Innovation as Global AI Expansion Accelerates